Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM. Taspoglutide (R1583, BIM51077) activates the GLP-1 receptor. Taspoglutide has comparable affinity (affinity constant 1.1±0.2 nM) to the natural ligand (affinity constant 1.5±0.3 nM) for the hGLP-1 receptor and exhibits comparable potency in stimulating cAMP production.
Taspoglutide in Sprague-Dawley rats and diabetic db/db mice have shown a dose-related enhancement of glucose-dependent insulin release, which lower blood glucose in the db/db mouse model of type 2 diabetes.
Molecular Weight | 3339.71 |
Formula | C152H232N40O45 |
CAS Number | 275371-94-3 |
Solubility (25°C) | DMSO 40 mg/mL |
Storage | -20°C, protect from light, dry, sealed |
Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
Related GLP Receptor Products |
---|
Amycretin
Amycretin is a novel, potentially first-in-class, long-acting co-agonist of GLP-1 and the amyloid receptor (AMYR) for obesity-related studies. |
NM-003
NM-003 is a GLP-2R agonist that can be used in studies related to inflammatory bowel disease. |
NB-1002
NB-1002 is a GLP-2R agonist that can be used in studies related to short bowel syndrome. |
MOD-15014
MOD-15014 is a GLP-2R modulator that can be used in studies related to short bowel syndrome. |
HM-15912
HM-15912 is a GLP-2R agonist that can be used in studies related to short bowel syndrome. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.